Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Value calls vindicated in August

Tue, 01st Sep 2020 13:00

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

VALUE CALLS VINDICATED IN AUGUST (1159 GMT)

The rising calls to invest in 'value' these last three months have often been met with a
fair whack of scepticism given the awful performance of that investment style in 2020 and the
irresistible surge of Fangs and tech.

Yet, trading in August has pretty much vindicated those who believed that, like they've
often done in the past, rising markets would progressively lift up cheap laggards as the
economic recovery gradually unfolds.

In its dashboard for August, S&P Dow Jones Indices shows how value in Europe outperformed
rival investment styles with a 6.3% monthly rise and a 9.7% jump over the last three months.

Year-to-date though, it's still a 29% fall, which probably means that value ain't causing
that much FOMO so far this year in comparison with say... buying a position in Apple or Tesla!

Here's the S&P Dow Jones Indices Dashboard for Europe:

More on the value theme these last few weeks:

LIVE MARKETS-Value sirens singing the blues

LIVE MARKETS-Actually, talking about value...

LIVE MARKETS-Another value call

LIVE MARKETS-Does U.S. election mean rotation towards value?

LIVE MARKETS-The value value-trap

LIVE MARKETS-Is it value stocks' time?

(Julien Ponthus)

*****

MORE CONCERNS ON SOUTHERN EUROPEAN BANKS (1012 GMT)

Policy response from governments and the European central bank has been strong, the EU
Recovery fund was a major milestone supporting the sector, but most Southern Europe bank shares
are already fully valued, according to some analysts.

Today Europe’s banks are down 1.7%, while the STOXX 600 index is flat with the tech sector
leading gains up 1.5%.

“We would argue the 'value' argument across some names is now is less clear-cut,” a
Jefferies research report says.

The main issue is the economic impact of the second wave of coronavirus infections which has
hit Europe as “the mid-term outlook remains challenged and, despite some pick-up in inflation
expectations, Euribor rates and futures continue to move lower,” it adds.

“While we are broadly aligned with consensus profit expectations in 2022 (on average), we
sit around 10% below consensus on 2022 pre-provision numbers which tempers our enthusiasm.”

Jefferies top picks are Intesa Sanpaolo, Caixabank and Bankia, while the
broker continues to like Unicaja.

(Stefano Rebaudo)

*****

STOXX 600 DOWN? BLAME THE BRITS! (0912 GMT)

There's no need to beat around the bush: if the STOXX 600 is slightly down (-0.1%) this
morning it's all because of London-listed stocks.

Quite striking how the first 32 losers on the pan-European index are ALL London-listed:

As put by AJ Bell analyst Russ Mould, the FTSE "was nursing a hangover after the Bank
Holiday" and was down over 1.3%.

"Not helping the FTSE’s cause was strength in sterling relative to the dollar, a currency
move which impacts the relative weight of the overseas earnings which dominate the index", Mould
added.

Looking at other European bourses, Germany's DAX is doing quite well, up 0.4% and Milan's
FTSE MIB is still in positive territory.

But looking at 2020 so far this year, the underperformance of the FTSE 100 is becoming a key
feature of the COVID-19 vintage.

Here's the FTSE 100 (blue) against the EURO STOXX 50 and the S&P 500:

(Julien Ponthus)

*****

OPENING SNAPSHOT: TECH AND HEALTH CARE SECTORS LEAD GAINS (0728 GMT)

Tech shares, particularly iPhone suppliers, are leading gains in the European stock market
after a press report that Apple Inc has asked suppliers to make at least 75 million 5G
iPhones for later this year, along with new Apple Watch models, a new iPad Air and a smaller
HomePod.

Among Apple suppliers Dialog Semi stocks are up 2.2%, STMicro shares rise
1%, Infineon shares up 1.6%.

The STOXX 600 index is up 0.7% with the tech sector up 1.5%. The healthcare sector is rising
1.2% after AstraZeneca said they could have data to ask U.S. emergency use authorization
or approval of their COVID-19 vaccines in the short term.

Risk sentiment is supported by a strong survey from China, while concerns about pandemic
trajectories continue to weigh. Travel and leisure stocks are the worst performers
sliding 1%, banks continue to lag behind, down 0.2%.

(Stefano Rebaudo)

*****

ON THE RADAR: ASTRAZENECA, APPLE SUPPLIERS, SUEZ

European equities are set to open higher after yesterday’s fall as a strong survey from
China propped up risk sentiment across Europe.

Apple suppliers look poised to gain on report that the world's largest company has
asked suppliers to make at least 75 million 5G iPhones for later this year. Dialog Semi
, STMicro, Infineon and other European chipmakers under spotlight.

Encouraging news on the coronavirus front as AstraZeneca, which is working with
Oxford University researchers, and Pfizer with partner BioNTech, said they
could have data by October to support U.S. emergency use authorization or approval of their
vaccines.

Meanwhile, Sanofi shares could come under pressure after the French pharma major
said its Kevzara drug trial didn't meet main goal in Covid-19 study.

In other key French moves, Suez, which saw its shares rise around 25% after
yesterday’s Veolia offer, said an unsolicited takeover approach carried "great
uncertainties" and it reiterated its confidence as an independent company.

Vivendi and activist fund Amber Capital - the two biggest shareholders in French
company Lagardere - said they would go to court over Lagardere's refusal to hold a
special shareholders meeting.

Roche received approval from the United States Food and Drug Administration for its
Cobas qualitative testing systems to confirm HIV diagnosis.

Apple suppliers

Seadrill proposed to creditors to turn over its stakes in oil services firms
Archer and Seadrill Seabras to redeem its outstanding secured notes.

Shares in Rocket Internet are up 2.6% in premarket trade after the company
announced a delisting plan.

(Stefano Rebaudo)

*****

MORNING CALL: IN THE BLACK BUT WITH VIRUS CONCERNS (0533 GMT)

European stock futures are in the black this morning along with their U.S. peers, but
concerns about the economic impact of the pandemic after the summer break are still in place.

China's factory activity which expanded at the fastest clip in nearly a decade in August,
bolstered by the first increase in new export orders this year, is supporting risk sentiment in
the continent after driving Asian shares in positive territory.

Expectations of long-lasting fiscal and monetary stimulus are also propping up equities, but
pandemic trajectories are expected to be the main investors focus in the fall, at least until a
vaccine is at hand.

(Stefano Rebaudo)

*****

More News
27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation reading later in the week.

Read more
26 Mar 2024 10:18

China to speed up 'new productive forces', vice president says

BEIJING, March 26 (Reuters) - China will accelerate the development of "new productive forces" and bolster stability and security for the global economy, Vice President Han Zheng told an investment forum in Beijing, as the world's no.2 economy seeks to reassure anxious foreign firms.

Read more
25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central bank decisions and accompanying statements which investors saw as dovish.

Read more
25 Mar 2024 09:04

LONDON MARKET OPEN: FTSE 100 treads water, FTSE 250 declines

(Alliance News) - The FTSE 100 in London traded flat early Monday, while the pound remained below the USD1.26 mark, as Bank of England Governor Andrew Bailey suggested rate cuts may happen soon.

Read more
25 Mar 2024 08:40

TOP NEWS: AstraZeneca wins US approval for rare nervous system disease

(Alliance News) - AstraZeneca PLC on Monday said its Ultomiris treatment has been approved by the US Food & Drug Administration as the first and only long-acting C5 complement inhibitor to treat neuromyelitis optica spectrum disorder in adults.

Read more
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.